CLAIMS

1. A method for immunizing a patient against influenza virus, comprising steps of (i) administering to a subject an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, and later (ii) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, wherein the first and second clades are different from each other, and wherein one or both of the immunogenic compositions is adjuvanted.

2. A method for immunizing a patient against influenza virus, comprising steps of (i) administering to a subject an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, and later (ii) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, wherein the first and second clades are different from each other, and wherein one or both of the immunogenic compositions includes influenza A virus neuraminidase antigen.

3. A method for immunizing a patient against influenza virus, comprising a step of administering to a subject an immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, wherein the patient has previously received an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, wherein the first and second clades are different from each other, and wherein the composition comprising the second clade antigen is adjuvanted and/or includes influenza A virus neuraminidase antigen.

4. A method for immunizing a patient against influenza virus, comprising steps of (i) administering to a subject an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, and later (ii) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, wherein the first and second clades are different from each other and the first clade is not clade 0.

5. A method for immunizing a patient against influenza virus, comprising steps of (i) administering to a subject an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, and later (ii) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, wherein the first and second clades are different from each other, and wherein one or both of the compositions contains $\leq$15μg of H5 hemagglutinin per dose.

6. The method of any preceding claim, where the first clade is clade 1 and the second clade is clade 2

7. The method of any preceding claim, where the first clade is clade 2 and the second clade is clade 1

8. The method of any preceding claim, where the first clade is clade 1 and the second clade is not clade 2.

9. The method of any preceding claim, where the first clade is clade 2 and the second clade is not clade 1.

10. The method of any preceding claim, wherein at least one of the immunogenic compositions is a split virion virus.

11. The method of any preceding claim, wherein at least one of the immunogenic compositions includes influenza A virus neuraminidase.

12. The method of any preceding claim, wherein the composition comprising the first clade antigen is adjuvanted.

13. The method of any preceding claim, wherein the composition comprising the second clade antigen is adjuvanted.

14. The method of any preceding claim, wherein the composition comprising the first clade antigen is adjuvanted and the composition comprising the second clade antigen is adjuvanted.

15. An immunogenic composition comprising hemagglutinin antigens from more than one clade of H5 influenza A virus.

16. The composition of claim 15, comprising hemagglutinin from clades 1 and 2 of H5 influenza A virus.

17. The composition of claim 15 or claim 16, wherein the composition is adjuvanted (*e.g.* with a submicron oil-in-water emulsion).

18. The composition of any one of claims 15 to 17, wherein the composition contains less than 45µg of H5 hemagglutinin per clade.

19. The composition of claim 18, wherein the composition contains less than 15µg of H5 hemagglutinin per clade *e.g.* 7.5µg per clade or 3.75µg per clade.

20. The composition of any one of claims 17 to 19, containing split virion antigen or purified surface antigen, and a submicron oil-in-water emulsion adjuvant.

21. The composition of claim 17 or claim 20, wherein the emulsion comprises squalene.

22. The composition of claim 21, wherein the composition contains 7.5μg HA per H5 clade.

23. The composition of claim 21, wherein the composition contains 3.75μg HA per H5 clade.

24. The composition of any one of claims 15-23, which is a 2-valent vaccine composition.

CLAIMS

1. An immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, for use in a method for immunizing a subject against influenza virus comprising steps of (i) administering to the subject the immunogenic composition comprising hemagglutinin antigen from the first clade of H5 influenza A virus, and later (ii) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, wherein the first and second clades are different from each other, and wherein:
   (a) the composition comprising the first clade antigen is adjuvanted and/or the composition comprising the second clade antigen is adjuvanted;
   (b) the antigen from the first clade and/or from the second clade comprises neuraminidase from the H5 virus;
   (c) the first clade is not clade 0; or
   (d) the composition comprising the first clade antigen contains 0.1-15μg of hemagglutinin from the first clade H5 influenza A virus and/or the composition comprising the second clade antigen contains 0.1-15μg of hemagglutinin from the second clade H5 influenza A virus.

2. An immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, for use in a method for immunizing a subject against influenza virus comprising steps of (i) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, and later (ii) administering to the subject the immunogenic composition comprising hemagglutinin antigen from the second clade of H5 influenza A virus, wherein the first and second clades are different, and wherein:
   (a) the composition comprising the first clade antigen is adjuvanted and/or the composition comprising the second clade antigen is adjuvanted;
   (b) the antigen from the first clade and/or from the second clade comprises neuraminidase from the H5 virus;
   (c) the first clade is not clade 0; or
   (d) the composition comprising the first clade antigen contains 0.1-15μg of hemagglutinin from the first clade H5 influenza A virus and/or the composition comprising the second clade antigen contains 0.1-15μg of hemagglutinin from the second clade H5 influenza A virus.

3. The immunogenic composition of claim 1 or claim 2, where:
   - the first clade is clade 1 and the second clade is clade 2.
   - the first clade is clade 2 and the second clade is clade 1.
   - the first clade is clade 1 and the second clade is not clade 2.
   - the first clade is clade 2 and the second clade is not clade 1.

4. The immunogenic composition of any preceding claim, wherein at least one of the immunogenic compositions is a split virion virus.

5. The immunogenic composition of any preceding claim, wherein at least one of the immunogenic compositions includes influenza A virus neuraminidase.

6. The immunogenic composition of any preceding claim, wherein the composition comprising the first clade antigen is adjuvanted.

7. The immunogenic composition of any preceding claim, wherein the composition comprising the second clade antigen is adjuvanted *e.g.* wherein the composition comprising the first clade antigen is adjuvanted and the composition comprising the second clade antigen is adjuvanted.

8. An immunogenic composition comprising hemagglutinin antigens from more than one clade of H5 influenza A virus.

9. The composition of claim 8, comprising hemagglutinin from clades 1 and 2 of H5 influenza A virus.

10. The composition of claim 8 or claim 9, wherein the composition is adjuvanted (*e.g.* with a submicron oil-in-water emulsion).

11. The composition of any one of claims 8 to 10, wherein the composition contains between 0.1 and 50μg of hemagglutinin per H5 clade.

12. The composition of claim 11, wherein the composition contains 0.1-15μg of hemagglutinin per H5 clade *e.g.* 7.5μg per clade or 3.75μg per clade.

13. The composition of any one of claims 10 to 12, containing whole virion antigens and an aluminium salt adjuvant (*e.g.* an aluminium hydroxide and/or an aluminium phosphate).

14. The composition of claim 13, wherein the viruses used as the source of the antigens are grown on cell culture (*e.g.* Vero cells) and the composition is free from ovalbumin and ovomucoid.

15. The composition of any one of claims 10 to 12, containing: split virion antigen or purified surface antigen; and a submicron oil-in-water emulsion adjuvant.

16. The composition of claim 10 or claim 15, wherein the emulsion comprises squalene.

17. The composition of claim 16, wherein the composition contains 7.5μg HA per H5 clade or 3.75μg HA per H5 clade.

18. The composition of any one of claims 8-17, which is a 2-valent vaccine composition.